Grouplp Column News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Grouplp column. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Grouplp Column Today - Breaking & Trending Today

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Receives $6.17 Average Price Target from Brokerages

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target […] ....

United States , Grouplp Column , Biopharmaceuticals Company Profile , Ngm Biopharmaceuticals Inc , Biopharmaceuticals Inc , Mackenzie Financial Corp , Get Rating , Director Group , Financial Corp , Employees Retirement System , Street Group , Ngm Biopharmaceuticals , Nasdaq Ngm ,

NGM Biopharmaceuticals, Inc. to Post FY2023 Earnings of ($1.79) Per Share, B. Riley Forecasts (NASDAQ:NGM)

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) – Analysts at B. Riley reduced their FY2023 EPS estimates for shares of NGM Biopharmaceuticals in a research note issued to investors on Wednesday, March 29th. B. Riley analyst M. Mamtani now expects that the company will earn ($1.79) per share for the year, down from their previous […] ....

Hong Kong , Grouplp Column , Hsbc Holdings , Hong Kong Ltd , Biopharmaceuticals Inc , Ngm Biopharmaceuticals Inc , Pricet Rowe Associates Inc , Get Rating , Director Group , Jin Long Chen , Kong Ltd , Ngm Biopharmaceuticals , Nasdaq Ngm , Earnings Estimates , B Riley ,

B. Riley Cuts NGM Biopharmaceuticals (NASDAQ:NGM) Price Target to $7.00

NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) had its target price decreased by B. Riley from $8.00 to $7.00 in a research report sent to investors on Thursday morning, The Fly reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for NGM Biopharmaceuticals’ Q1 2023 earnings at ($0.52) EPS, […] ....

Hong Kong , Hong Kong Ltd , Biopharmaceuticals Inc , Grouplp Column , Pricet Rowe Associates Inc , Securities Exchange Commission , Hsbc Holdings , Get Rating , Director Group , Exchange Commission , Kong Ltd , Ngm Biopharmaceuticals , Nasdaq Ngm , Lower Price Target , B Riley ,

Morgan Stanley Raises Endeavour Mining (OTCMKTS:EDVMF) Price Target to C$36.00

NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) had its price target decreased by B. Riley from $8.00 to $7.00 in a research note issued to investors on Thursday, The Fly reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for NGM Biopharmaceuticals’ Q1 2023 earnings at ($0.52) EPS, Q2 […] ....

Hong Kong , Hsbc Holdings , Pricet Rowe Associates Inc , Grouplp Column , Biopharmaceuticals Inc , Hong Kong Ltd , Get Rating , Jin Long Chen , Director Group , Kong Ltd , Ngm Biopharmaceuticals , Nasdaq Ngm , Lower Price Target , B Riley ,

Deutsche Bank AG Grows Position in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM)

Deutsche Bank AG increased its holdings in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) by 53.5% in the second quarter, Holdings Channel.com reports. The firm owned 263,912 shares of the company’s stock after purchasing an additional 92,018 shares during the period. Deutsche Bank AG’s holdings in NGM Biopharmaceuticals were worth $3,384,000 at the end of […] ....

United States , Davidv Goeddel , Raymond James , Piper Sandler , Biopharmaceuticals Company Profile , Board Of Administration Florida Retirement System , Principal Financial Group Inc , Grouplp Column , Deutsche Bank , Connor Clark Lunn Investment Management Ltd , Biopharmaceuticals Inc , Jpmorgan Chase Co , Washington University , Jefferies Financial Group , Holdings Channel , Get Rating , Financial Group , Florida Retirement System , Connor Clark , Lunn Investment Management , Director Group , Director David , Visit Holdingschannel , Ngm Biopharmaceuticals , Nasdaq Ngm , Sec Filings ,